Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Parkinson Disease, Falls Patient

In brief

This will be a Phase II single center, double-blind, randomized, placebo-controlled, efficacy study. Subjects will complete six visits. The first will be a screening visit. There will be four assessment visits: baseline, 2 weeks after the double-blinded trial begins, the end of the blinded trial, and after 4 weeks of washout. There will also be an additional randomization and medication dispensing visit immediately following the dose optimization period and preceding the double-blinded trial.

Key facts

Study ID: NCT03567447
Run by: St. Joseph's Hospital and Medical Center, Phoenix
People needed: 10
Starts: 2018-08-17
Expected to finish: 2020-03-01
Last updated by the study team: 2019-10-29

Who can join

Age: 30 and older, up to 83. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subject has voluntarily signed and dated an informed consent form (ICF), approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study.
Subject is male or female and is ≥ 30 and ≤ 83 years of age.
Parkinson's diagnosis with history of falls or gait difficulty.
Subject demonstrates neurogenic orthostatic hypotension (drop of 20 mm/Hg Systolic or 10 mm/Hg diastolic or both within 3 min of standing)
Fell more than once in past year.
Montreal Cognitive Assessment (MoCA) score ≥ 21.
Stable dose of levodopa, dopamine agonist, amantadine, and/or monoamine oxidase B inhibitor, i.e. unchanged for 1 month.
Subject is ambulatory and able to walk ≥ 10 meters with/without the use of an assistive device.

You may not qualify if…

Subject has a clinical diagnosis of an atypical Parkinsonism
Subject has a clinical diagnosis of PD that is suspicious to the investigator as being a possible case of atypical Parkinson's
History of significant psychiatric illness such as schizophrenia or bipolar affective disorder or any other significant psychiatric illness that in the opinion of the investigator would interfere with participation in the study; history of major depressive disorder in the past year, or current major depressive episode
Patients with systolic BP ≤70 mm/hg
Subjects with a history of coronary artery disease or congestive heart failure
Participation in another investigational drug or device study in during the 60 days prior to the Screening Visit
Treatment with any anti-hypertensive medications
Treatment with any anti-spasmodic medications
Treatment with medications intended to elevate blood pressure
Treatment with non-specific monoamine oxidase (MAO) inhibitors

Where it is running

Barrow Neurological Institute at St. Joseph's Hospital and Medical Center — Phoenix, Arizona, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.